Tag Archives: EKSO BIONICS

The President of EKSO BIONICS (NASDAQ: EKSO) is Selling Shares

Today, the President of EKSO BIONICS (NASDAQ: EKSO), Russ Angold, sold shares of EKSO for $175.5K. Following Russ Angold’s last EKSO Sell transaction on September 05, 2017, the stock climbed by 1.7%. Based on EKSO BIONICS’s latest earnings report for

The CFO of EKSO BIONICS (NASDAQ: EKSO) is Buying Shares

Today, the CFO of EKSO BIONICS (NASDAQ: EKSO), Max Scheder-Bieschin, bought shares of EKSO for $3,990. Following this transaction Max Scheder-Bieschin’s holding in the company was increased by 11.34% to a total of $253K. In addition to Max Scheder-Bieschin, one

The President & Chief Com. Officer of EKSO BIONICS (NASDAQ: EKSO) is Buying Shares

Today, the President & Chief Com. Officer of EKSO BIONICS (NASDAQ: EKSO), Tom Looby, bought shares of EKSO for $3,980. This recent transaction increases Tom Looby’s holding in the company by 166.67% to a total of $16.4K. The company has

Analysts Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 experts just weighed in on EKSO BIONICS HOLDING (NASDAQ: EKSO) and Caladrius Biosciences Inc. (NASDAQ: CLBS) with bullish sentimens. EKSO BIONICS HOLDING (NASDAQ: EKSO) In a report

Rodman & Renshaw Thinks EKSO BIONICS’s Stock is Going to Recover

Rodman & Renshaw analyst Amit Dayal assigned a Buy rating to EKSO BIONICS (NASDAQ: EKSO) yesterday and set a price target of $3. The company’s shares opened today at $0.83, close to its 52-week low of $0.65.Dayal noted, “FDA approval

Rodman & Renshaw Thinks EKSO BIONICS’s Stock is Going to Recover

In a report released yesterday, Amit Dayal from Rodman & Renshaw maintained a Buy rating on EKSO BIONICS (NASDAQ: EKSO), with a price target of $3. The company’s shares closed yesterday at $0.87, close to its 52-week low of $0.65.